Approved more than two decades ago and generating roughly $20 billion in sales, Tamiflu never underwent rigorous randomized trials in the sickest patients.
As America turns 250, IMA is looking back at what medicine gained, what it lost and what must now be restored: honest, independent, patient-centered care.





